(MedPage Today) — DENVER — Treatment-resistant dermatomyositis improved significantly with the investigational TYK2/JAK1 inhibitor brepocitinib, according to a randomized trial.
The higher of two doses of brepocitinib improved the total dermatomyositis…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
